S3V Vascular Technology Limited has called an Extra-Oridinary General Meeting (EGM) on June 22, 2026. The idea is to seek confirmation from the shareholders and move ahead to raise the fund amount of ₹11.51 crore. The allotment will be spread across 15 investors, that includes new individual investors and promoters.
About S3V Vascular Technologies Limited
S3V Vascular Technologies Limited is a medical device company with a registered office at Hootagalli Industrial Area, Mysore Karnataka. The establishment operates in the Vascular Technology space.
Their prime motive is “Uncompromised Quality, Unsurpassed Value”. The company focus on product innovation and regulatory compliance, the company is now actively seeking growth capital to accelerate its next phase of expansion.
What is the Agenda for S3V Vascular Technologies EGM 2026
An Extra-Ordinary General Meeting (EGM) is a special shareholders’ meeting which is called outside the regular Annual General Meeting.
In common, urgent corporate matters are addressed in EGMs. For S3V Vascular Technologies the EGM/001/2026-27 is called to approve the issuance of the equity shares on preferential basis.
On May 28th, 2026, the Board of Directors have already passed the resolution for this fundraise. Later, they declared the EGM is scheduled for June 22, 2026 at its Mysore Office.
Key Fundraise at a Glance
Parameter | Details |
EGM Date | Monday, June 22, 2026 |
Meeting Number | EGM/001/2026-27 |
Type of Issue | Preferential Allotment / Private Placement |
No. of Equity Shares | 2,09,390 Shares |
Face Value | ₹10 per share |
Issue Price | ₹550 per share |
Share Premium | ₹540 per share |
Total Amount to be Raised | ₹11,51,64,500 (₹11.51 Crore) |
Record Date | May 22, 2026 |
Valuation Date | March 31, 2026 |
Valuer | CA Dhruva Hegde, Registered Valuer (IBBI) |
Allotment Deadline | Within 90 days of shareholder approval |
Where will the Funds be used by S3V Vascular Technologies?
The company has outlined five key areas for deploying the ₹11.51 crore raised through this preferential allotment:
1. Regulatory Approvals:
Obtaining CE certification and other international regulatory clearance for its vascular technology products. CE Marking is mandatory to sell medical devices across the European Union. S3V has been pursuing this certification for its stents and neuro-vascular devices since 2012. During their ₹300 crore Series B raise in March 2024, the company explicitly states plans to seek US FDA and European regulatory approvals to begin exports to Asian, Middle East, and East European Market.
2. Product Development and Clinical Trials:
S3V operates across Neuro, Cardiac, Spine, and Critical Care verticals and received a CDSCO license for class C& D devices in May 2025. The fund will support R& D and the clinical trials required to validate next-generation devices.
3. Technology & Infrastructure
The fundraise provides targeted capital to support the existing integrated manufacturing facility in Mysore.
4. Working Capital:
As production scales and export cycles lengthen, working capital ensures uninterrupted operations across manufacturing and distribution.
5. General Purpose:
With pre-IPO investors already active in the secondary market, this may also support governance and IPO-readiness expenses.
Source: ET
What Does This Mean for Existing Shareholders?
For existing shareholders, a few key points stand out:
Dilution is Minimal: Promoters stake drops by just ~0.35%; but the public holding remains largely intact.
Growth Signal: The fundraise is earmarked for CE certification and product development. This could also unlock international revenue streams for the company.
Promoter Confidence: The promoters themselves are subscribing to 18,650 shares worth Rs.1.02 crore in this round signals internal confidence in the company’s prospects.
Conclusion
S3V Vascular Technologies Limited’s ₹11.51 crore fundraise via preferential allotment marks a significant step in the company’s growth journey. With minimal equity dilution, promoter participation, and a Registered Valuer-backed issue price, this fundraise appears well-structured and regulation compliant.
Exiting and potential investors should watch the allotment as it unfolds within 90 days of the June 22, 2026 EGM approval.
FAQs
What is the S3V Vascular Technologies EGM about?
The S3V Vascular Technology EGM is due for June 22, 2026. The idea is to get shareholder’s approval for a preferential allotment of 2,09,390 equity shares. Each share is priced at ₹550.
What is the issue price of the equity shares?
The equity shares are being issued at ₹550 shares (face value ₹10+ premium of ₹540). This is after SEBI-registered valuer based on March 31, 2026.
Who are the biggest investors in this private placement?
Sanjay K Agrawal is the largest external subscriber with shares worth ₹2.31 crore.
Is this allotment open to the public?
No. This is a private placement to specific identified investors.
